Abstract:Melatonin is an indolamine synthesized and secreted by the pineal gland along with other extrapineal sources including immune system cells, the brain, skin and the gastrointestinal tract. Growing interest in this compound as a potential therapeutic agent in several diseases stems from its pleiotropic effects. Thus, melatonin plays a key role in various physiological activities that include regulation of circadian rhythms, immune responses, the oxidative process, apoptosis or mitochondrial homeostasis. Most of these processes are altered during inflammatory pathologies, among which neurodegenerative and bowel diseases stand out. Therapeutic assays with melatonin indicate that it has a beneficial therapeutic value in the treatment of several inflammatory diseases, such as Alzheimer, Amiotrophic Lateral, Multiple Sclerosis and Huntigton´s disease as well as ulcerative colitis. However, contradictory effects have been demonstrated in Parkinson´s and Chron´s diseases, which, in some cases, the reported effects were beneficial while in others the pathology was exacerbated. These various results may be related to several factors. In the first place, it should be taken into account that at the beginning of the inflammation phase there is a production of reactive oxygen species (ROS) that should not be blocked by exclusively antioxidant molecules, since, on the one hand, it would be interfering with the action of neutrophils and macrophages and, on the other, with the apoptotic signals activated by ROS. It is also important to keep in mind that the end result of an anti-inflammatory molecule will depend on the degree of inflammation or whether or not it has been resolved and has therefore become chronic. In this review we present the use of melatonin in the control of inflammation underlying the above mentioned diseases. These actions are mediated through their receptors but also with their direct antioxidant action and melatonin's ability to break the vicious cycle of ROSinflammation. This review is aimed at evaluating the effect of melatonin on activity of the inflammatory process and at its immunomodulator effects.

Melatonin as a Mediator of the Gut Microbiota-Host Interaction: Implications for Health and Disease

Melatonin–Microbiome Two-Sided Interaction in Dysbiosis-Associated Conditions

Microbial melatonin metabolism in the human intestine as a therapeutic target for dysbiosis and rhythm disorders

Melatonin mediates mucosal immune cells, microbial metabolism, and rhythm crosstalk: A therapeutic target to reduce intestinal inflammation

Gut microbiota in neurological diseases: Melatonin plays an important regulatory role

Role of Melatonin in the Inflammatory Process and its Therapeutic Potential

Melatonin’s Impact on Antioxidative and Anti-Inflammatory Reprogramming in Homeostasis and Disease

Melatonin Attenuates Microbiota Dysbiosis of Jejunum in Short-Term Sleep Deprived Mice

A New Paradigm in the Relationship between Melatonin and Breast Cancer: Gut Microbiota Identified as a Potential Regulatory Agent

Melatonin and Health: Insights of Melatonin Action, Biological Functions, and Associated Disorders

Distribution, Function And Physiological Role Of Melatonin In The Lower Gut

Molecular Mechanisms of Melatonin-Mediated Cell Protection and Signaling in Health and Disease

Melatonin from an Antioxidant to a Classic Hormone or a Tissue Factor: Experimental and Clinical Aspects 2019

The Role of Aeromonas-Goblet Cell Interactions in Melatonin-Mediated Improvements in Sleep Deprivation-Induced Colitis

Melatonin-mediated corrective changes in gut microbiota of experimentally chronodisrupted C57BL/6J mice

Is Melatonin the Cornucopia of the 21st Century?

Evaluating the Oxidative Stress in Inflammation: Role of Melatonin

Therapeutic potential of melatonin in colorectal cancer: Focus on lipid metabolism and gut microbiota

Melatonin and oral diseases: possible therapeutic roles based on cellular mechanisms

Gut microbiota and sleep: Interaction mechanisms and therapeutic prospects

Potential therapeutic role of melatonin in hepatobiliary diseases: current evidence and clinical observations